Next-generation metabolomics in lung cancer diagnosis, treatment and precision medicine: mini review

Li Yu; Kefeng Li; Xiaoye Zhang

doi:10.18632/oncotarget.22404

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Next-generation metabolomics in lung cancer diagnosis, treatment and precision medicine: mini review

Li Yu, Kefeng Li and Xiaoye Zhang _

PDF | HTML | How to cite

Oncotarget. 2017; 8:115774-115786. https://doi.org/10.18632/oncotarget.22404

Metrics: PDF 2376 views | HTML 6529 views | ?

Abstract

Li Yu1, Kefeng Li2 and Xiaoye Zhang1

1Department of Oncology, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China

2School of Medicine, University of California San Diego, San Diego, CA, USA

Correspondence to:

Xiaoye Zhang, email: [email protected]

Keywords: next-generation metabolomics; lung cancer; precision medicine; biomarker; pathogenesis

Received: May 24, 2017 Accepted: September 21, 2017 Published: November 11, 2017

ABSTRACT

Lung cancer is the leading cause of cancer-related death. Next-generation metabolomics is becoming a powerful emerging technology for studying the systems biology and chemistry of health and disease. This mini review summarized the main platforms of next-generation metabolomics and its main applications in lung cancer including early diagnosis, pathogenesis, classifications and precision medicine. The period covers between 2009 and August, 2017. The major issues and future directions of metabolomics in lung cancer research and clinical applications were also discussed.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22404

Publication Alerts

Reviews:

Next-generation metabolomics in lung cancer diagnosis, treatment and precision medicine: mini review

Abstract